{
    "nctId": "NCT00005956",
    "briefTitle": "Biological Therapy in Treating Patients With Advanced Cancer",
    "officialTitle": "A Pilot Study of Active Immunotherapy With HER2/Neu Intracellular Domain (ICD) Protein-Pulsed, Autologous, Cultured Dendritic Cells in Patients With No Evidence of Disease After Standard Treatment for HER2/Neu Expressing Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Gastric Cancer, Ovarian Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "Safety",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed advanced malignancy that expresses HER2/neu\n\n  * Stage IIA breast cancer with more than 6 positive lymph nodes\n  * Stage IIB, IIIA, or IIIB breast cancer\n  * Stage III ovarian cancer\n  * Lymph node positive gastric cancer\n  * Metastatic tumor\n* No measurable or evaluable disease after standard treatment\n* No previously irradiated or newly diagnosed CNS metastases\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 and over\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* Karnofsky 80-100%\n\nLife expectancy:\n\n* Greater than 6 months\n\nHematopoietic:\n\n* WBC at least 3,000/mm\\^3\n* Hemoglobin at least 9 mg/dL\n* Platelet count at least 100,000/mm\\^3\n\nHepatic:\n\n* Bilirubin less than 2.0 mg/dL\n* No hepatic disease, including viral hepatitis\n\nRenal:\n\n* Creatinine less than 2.5 mg/dL\n\nCardiovascular:\n\n* No New York Heart Association class III or IV heart disease\n\nPulmonary:\n\n* No asthma or chronic obstructive pulmonary disease\n\nImmunologic:\n\n* Must have positive intradermal delayed hypersensitivity test for at least 1 of the following:\n\n  * Candida\n  * Mumps\n  * Tetanus\n  * Trichophyton\n  * Histoplasmin\n* No prior autoimmune disease including, but not limited to, the following:\n\n  * Inflammatory bowel disease\n  * Systemic lupus erythematosus\n  * Ankylosing spondylitis\n  * Scleroderma\n  * Multiple sclerosis\n\nOther:\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* HIV negative\n* Hepatitis B surface antigen and hepatitis C antibody negative\n* No other concurrent serious chronic or acute illness or infection (including urinary tract infection)\n* No known shellfish or iodine allergy\n* No other prior or concurrent malignancy except for nonmelanoma skin cancer, cervical cancer, or controlled superficial bladder cancer\n* No medical or psychological condition that may preclude study\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* No other concurrent immunotherapy\n\nChemotherapy:\n\n* At least 4 weeks since prior chemotherapy and recovered\n* No concurrent chemotherapy\n\nEndocrine therapy:\n\n* Concurrent hormonal therapy allowed (tamoxifen, raloxifene, toremifene, and all aromatase inhibitors)\n* At least 4 weeks since prior steroid or immunosuppressive therapy (e.g, azathioprine or cyclosporine)\n\nRadiotherapy:\n\n* Prior radiotherapy allowed except to cranium\n* At least 4 weeks since prior radiotherapy and recovered\n* At least 12 weeks since prior strontium chloride Sr 89\n* No concurrent radiotherapy\n\nSurgery:\n\n* At least 4 weeks since prior surgery and recovered\n\nOther:\n\n* Concurrent bisphosphonates allowed\n* No prior hepatitis B immunization",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}